nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0867	0.143	CbGbCtD
Sitaxentan—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0867	0.143	CbGbCtD
Sitaxentan—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0721	0.119	CbGbCtD
Sitaxentan—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0721	0.119	CbGbCtD
Sitaxentan—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0553	0.0914	CbGbCtD
Sitaxentan—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0546	0.0903	CbGbCtD
Sitaxentan—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0374	0.0618	CbGbCtD
Sitaxentan—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0364	0.0602	CbGbCtD
Sitaxentan—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0357	0.0589	CbGbCtD
Sitaxentan—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0318	0.0525	CbGbCtD
Sitaxentan—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0186	0.0308	CbGbCtD
Sitaxentan—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0176	0.0291	CbGbCtD
Sitaxentan—EDNRA—Endothelins—EDN1—chronic obstructive pulmonary disease	0.000958	0.00874	CbGpPWpGaD
Sitaxentan—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000916	0.00836	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—MMP1—chronic obstructive pulmonary disease	0.000805	0.00735	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Other—ADRB2—chronic obstructive pulmonary disease	0.000799	0.00729	CbGpPWpGaD
Sitaxentan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000779	0.00711	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000773	0.00705	CbGpPWpGaD
Sitaxentan—CYP2C19—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.00073	0.00666	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CXCR2—chronic obstructive pulmonary disease	0.000707	0.00645	CbGpPWpGaD
Sitaxentan—CYP2C19—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000702	0.00641	CbGpPWpGaD
Sitaxentan—CYP2C9—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000666	0.00607	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000662	0.00604	CbGpPWpGaD
Sitaxentan—CYP2C9—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00064	0.00584	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Other—HTR2A—chronic obstructive pulmonary disease	0.000625	0.0057	CbGpPWpGaD
Sitaxentan—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000604	0.00551	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000561	0.00512	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.000554	0.00505	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000553	0.00505	CbGpPWpGaD
Sitaxentan—CYP2C19—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000542	0.00495	CbGpPWpGaD
Sitaxentan—CYP2C19—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000531	0.00484	CbGpPWpGaD
Sitaxentan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000525	0.00479	CbGpPWpGaD
Sitaxentan—CYP2C19—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00051	0.00466	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000504	0.0046	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000502	0.00458	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000491	0.00448	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000485	0.00443	CbGpPWpGaD
Sitaxentan—CYP2C9—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000484	0.00441	CbGpPWpGaD
Sitaxentan—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000478	0.00436	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000474	0.00433	CbGpPWpGaD
Sitaxentan—CYP2C9—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000465	0.00424	CbGpPWpGaD
Sitaxentan—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000458	0.00417	CbGpPWpGaD
Sitaxentan—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000439	0.00401	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000439	0.004	CbGpPWpGaD
Sitaxentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000436	0.00397	CbGpPWpGaD
Sitaxentan—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000422	0.00385	CbGpPWpGaD
Sitaxentan—CYP2C19—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000421	0.00384	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000416	0.00379	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000413	0.00377	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000401	0.00366	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.000396	0.00362	CbGpPWpGaD
Sitaxentan—CYP2C19—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000394	0.0036	CbGpPWpGaD
Sitaxentan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000381	0.00348	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000379	0.00346	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000371	0.00339	CbGpPWpGaD
Sitaxentan—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000366	0.00334	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000361	0.00329	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000359	0.00327	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000354	0.00323	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000351	0.0032	CbGpPWpGaD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000351	0.0032	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000347	0.00317	CbGpPWpGaD
Sitaxentan—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000347	0.00317	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000325	0.00296	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000321	0.00293	CbGpPWpGaD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00032	0.00292	CbGpPWpGaD
Sitaxentan—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000319	0.00291	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000316	0.00289	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000314	0.00286	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.00031	0.00283	CbGpPWpGaD
Sitaxentan—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000307	0.0028	CbGpPWpGaD
Sitaxentan—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000303	0.00277	CbGpPWpGaD
Sitaxentan—CYP2C19—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000299	0.00273	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.000299	0.00273	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000297	0.00271	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000296	0.0027	CbGpPWpGaD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000287	0.00262	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000285	0.0026	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000283	0.00258	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000283	0.00258	CbGpPWpGaD
Sitaxentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000276	0.00252	CbGpPWpGaD
Sitaxentan—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000273	0.00249	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000271	0.00248	CbGpPWpGaD
Sitaxentan—Tension—Arformoterol—chronic obstructive pulmonary disease	0.000268	0.000939	CcSEcCtD
Sitaxentan—Tension—Formoterol—chronic obstructive pulmonary disease	0.000268	0.000939	CcSEcCtD
Sitaxentan—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000267	0.000937	CcSEcCtD
Sitaxentan—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000267	0.000935	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000266	0.00242	CbGpPWpGaD
Sitaxentan—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.000265	0.000929	CcSEcCtD
Sitaxentan—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.000265	0.000929	CcSEcCtD
Sitaxentan—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000265	0.000928	CcSEcCtD
Sitaxentan—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000262	0.00092	CcSEcCtD
Sitaxentan—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000262	0.00092	CcSEcCtD
Sitaxentan—Increased appetite—Prednisolone—chronic obstructive pulmonary disease	0.000261	0.000916	CcSEcCtD
Sitaxentan—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000261	0.000914	CcSEcCtD
Sitaxentan—Hypercholesterolaemia—Prednisone—chronic obstructive pulmonary disease	0.00026	0.000911	CcSEcCtD
Sitaxentan—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000259	0.000909	CcSEcCtD
Sitaxentan—Visual disturbance—Prednisolone—chronic obstructive pulmonary disease	0.000259	0.000908	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000259	0.00236	CbGpPWpGaD
Sitaxentan—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000258	0.000903	CcSEcCtD
Sitaxentan—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000258	0.000903	CcSEcCtD
Sitaxentan—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.000257	0.000901	CcSEcCtD
Sitaxentan—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000256	0.000896	CcSEcCtD
Sitaxentan—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000256	0.000896	CcSEcCtD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000255	0.00233	CbGpPWpGaD
Sitaxentan—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000254	0.000892	CcSEcCtD
Sitaxentan—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000253	0.000888	CcSEcCtD
Sitaxentan—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000253	0.000888	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000253	0.00231	CbGpPWpGaD
Sitaxentan—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000253	0.000886	CcSEcCtD
Sitaxentan—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000251	0.000879	CcSEcCtD
Sitaxentan—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000251	0.000879	CcSEcCtD
Sitaxentan—Tremor—Montelukast—chronic obstructive pulmonary disease	0.00025	0.000878	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.00025	0.00228	CbGpPWpGaD
Sitaxentan—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.00025	0.000877	CcSEcCtD
Sitaxentan—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.00025	0.000875	CcSEcCtD
Sitaxentan—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000248	0.000869	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000247	0.00226	CbGpPWpGaD
Sitaxentan—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000246	0.000863	CcSEcCtD
Sitaxentan—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000246	0.000863	CcSEcCtD
Sitaxentan—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000246	0.00224	CbGpPWpGaD
Sitaxentan—Hiccups—Prednisone—chronic obstructive pulmonary disease	0.000246	0.000861	CcSEcCtD
Sitaxentan—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000246	0.000861	CcSEcCtD
Sitaxentan—Osteoarthritis—Prednisolone—chronic obstructive pulmonary disease	0.000245	0.00086	CcSEcCtD
Sitaxentan—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000243	0.000852	CcSEcCtD
Sitaxentan—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000241	0.000846	CcSEcCtD
Sitaxentan—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000239	0.000838	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000238	0.000835	CcSEcCtD
Sitaxentan—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000237	0.00083	CcSEcCtD
Sitaxentan—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000236	0.000827	CcSEcCtD
Sitaxentan—Skin exfoliation—Prednisone—chronic obstructive pulmonary disease	0.000235	0.000822	CcSEcCtD
Sitaxentan—Fluid retention—Prednisone—chronic obstructive pulmonary disease	0.000233	0.000818	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000233	0.00212	CbGpPWpGaD
Sitaxentan—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000233	0.000815	CcSEcCtD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000232	0.00212	CbGpPWpGaD
Sitaxentan—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000232	0.000815	CcSEcCtD
Sitaxentan—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000232	0.000815	CcSEcCtD
Sitaxentan—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000232	0.000815	CcSEcCtD
Sitaxentan—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000232	0.000812	CcSEcCtD
Sitaxentan—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000231	0.000811	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000231	0.000809	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000231	0.000809	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.00023	0.0021	CbGpPWpGaD
Sitaxentan—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00023	0.000805	CcSEcCtD
Sitaxentan—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00023	0.000805	CcSEcCtD
Sitaxentan—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.000797	CcSEcCtD
Sitaxentan—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000227	0.000797	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000226	0.00207	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000226	0.000792	CcSEcCtD
Sitaxentan—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000226	0.00206	CbGpPWpGaD
Sitaxentan—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000225	0.000789	CcSEcCtD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000224	0.00204	CbGpPWpGaD
Sitaxentan—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000223	0.000781	CcSEcCtD
Sitaxentan—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000223	0.000781	CcSEcCtD
Sitaxentan—Infection—Formoterol—chronic obstructive pulmonary disease	0.000221	0.000776	CcSEcCtD
Sitaxentan—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000221	0.000776	CcSEcCtD
Sitaxentan—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.00022	0.00201	CbGpPWpGaD
Sitaxentan—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000219	0.000769	CcSEcCtD
Sitaxentan—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000219	0.000769	CcSEcCtD
Sitaxentan—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000218	0.000766	CcSEcCtD
Sitaxentan—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000218	0.000766	CcSEcCtD
Sitaxentan—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000218	0.000765	CcSEcCtD
Sitaxentan—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000217	0.00198	CbGpPWpGaD
Sitaxentan—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000217	0.000762	CcSEcCtD
Sitaxentan—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000217	0.000762	CcSEcCtD
Sitaxentan—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000217	0.00076	CcSEcCtD
Sitaxentan—Infection—Montelukast—chronic obstructive pulmonary disease	0.000217	0.00076	CcSEcCtD
Sitaxentan—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000216	0.000759	CcSEcCtD
Sitaxentan—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000216	0.000758	CcSEcCtD
Sitaxentan—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000216	0.000758	CcSEcCtD
Sitaxentan—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000216	0.000756	CcSEcCtD
Sitaxentan—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.000752	CcSEcCtD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.000214	0.00195	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000214	0.00075	CcSEcCtD
Sitaxentan—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000214	0.000749	CcSEcCtD
Sitaxentan—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000212	0.000743	CcSEcCtD
Sitaxentan—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.00021	0.000737	CcSEcCtD
Sitaxentan—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000209	0.000732	CcSEcCtD
Sitaxentan—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000208	0.00073	CcSEcCtD
Sitaxentan—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000208	0.00073	CcSEcCtD
Sitaxentan—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000206	0.000723	CcSEcCtD
Sitaxentan—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000205	0.00072	CcSEcCtD
Sitaxentan—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000204	0.000716	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000204	0.00186	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000203	0.000713	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000202	0.00185	CbGpPWpGaD
Sitaxentan—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000201	0.000706	CcSEcCtD
Sitaxentan—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000201	0.000706	CcSEcCtD
Sitaxentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000201	0.00183	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000201	0.00183	CbGpPWpGaD
Sitaxentan—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.0002	0.000703	CcSEcCtD
Sitaxentan—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.0002	0.000702	CcSEcCtD
Sitaxentan—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000198	0.00181	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	0.000198	0.00181	CbGpPWpGaD
Sitaxentan—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000198	0.000694	CcSEcCtD
Sitaxentan—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000198	0.000694	CcSEcCtD
Sitaxentan—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000197	0.000692	CcSEcCtD
Sitaxentan—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000197	0.000689	CcSEcCtD
Sitaxentan—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000197	0.000689	CcSEcCtD
Sitaxentan—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000196	0.000687	CcSEcCtD
Sitaxentan—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000196	0.000687	CcSEcCtD
Sitaxentan—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000194	0.00068	CcSEcCtD
Sitaxentan—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000194	0.000678	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000192	0.000674	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000192	0.000674	CcSEcCtD
Sitaxentan—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000192	0.000673	CcSEcCtD
Sitaxentan—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000192	0.000673	CcSEcCtD
Sitaxentan—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000192	0.000673	CcSEcCtD
Sitaxentan—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.00019	0.000668	CcSEcCtD
Sitaxentan—Constipation—Formoterol—chronic obstructive pulmonary disease	0.00019	0.000668	CcSEcCtD
Sitaxentan—Pain—Formoterol—chronic obstructive pulmonary disease	0.00019	0.000668	CcSEcCtD
Sitaxentan—Pain—Arformoterol—chronic obstructive pulmonary disease	0.00019	0.000668	CcSEcCtD
Sitaxentan—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.00019	0.000667	CcSEcCtD
Sitaxentan—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.00019	0.000665	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.00019	0.00173	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000188	0.00066	CcSEcCtD
Sitaxentan—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000188	0.000659	CcSEcCtD
Sitaxentan—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000187	0.000655	CcSEcCtD
Sitaxentan—Pain—Montelukast—chronic obstructive pulmonary disease	0.000187	0.000654	CcSEcCtD
Sitaxentan—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000186	0.0017	CbGpPWpGaD
Sitaxentan—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000186	0.000654	CcSEcCtD
Sitaxentan—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000186	0.000652	CcSEcCtD
Sitaxentan—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000185	0.00065	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000185	0.00169	CbGpPWpGaD
Sitaxentan—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000185	0.000649	CcSEcCtD
Sitaxentan—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000185	0.000647	CcSEcCtD
Sitaxentan—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000184	0.000646	CcSEcCtD
Sitaxentan—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000184	0.000644	CcSEcCtD
Sitaxentan—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000184	0.000643	CcSEcCtD
Sitaxentan—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000184	0.000643	CcSEcCtD
Sitaxentan—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000183	0.000643	CcSEcCtD
Sitaxentan—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000183	0.000641	CcSEcCtD
Sitaxentan—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000183	0.000641	CcSEcCtD
Sitaxentan—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000183	0.00064	CcSEcCtD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000182	0.00166	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000182	0.000637	CcSEcCtD
Sitaxentan—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000181	0.000636	CcSEcCtD
Sitaxentan—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.00018	0.00164	CbGpPWpGaD
Sitaxentan—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.00018	0.00063	CcSEcCtD
Sitaxentan—Pain—Salbutamol—chronic obstructive pulmonary disease	0.00018	0.00063	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000179	0.00163	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000179	0.00163	CbGpPWpGaD
Sitaxentan—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000179	0.00163	CbGpPWpGaD
Sitaxentan—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000178	0.000625	CcSEcCtD
Sitaxentan—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000178	0.000625	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000177	0.00162	CbGpPWpGaD
Sitaxentan—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000177	0.00062	CcSEcCtD
Sitaxentan—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000177	0.00062	CcSEcCtD
Sitaxentan—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000176	0.000617	CcSEcCtD
Sitaxentan—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000176	0.000617	CcSEcCtD
Sitaxentan—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000175	0.000615	CcSEcCtD
Sitaxentan—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000174	0.00061	CcSEcCtD
Sitaxentan—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000174	0.000609	CcSEcCtD
Sitaxentan—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000174	0.000609	CcSEcCtD
Sitaxentan—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000173	0.000608	CcSEcCtD
Sitaxentan—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000173	0.000608	CcSEcCtD
Sitaxentan—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000173	0.000606	CcSEcCtD
Sitaxentan—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000173	0.000606	CcSEcCtD
Sitaxentan—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000172	0.000605	CcSEcCtD
Sitaxentan—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000171	0.000598	CcSEcCtD
Sitaxentan—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.00017	0.000595	CcSEcCtD
Sitaxentan—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.000586	CcSEcCtD
Sitaxentan—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000166	0.000583	CcSEcCtD
Sitaxentan—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000164	0.000575	CcSEcCtD
Sitaxentan—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000164	0.000575	CcSEcCtD
Sitaxentan—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000164	0.000575	CcSEcCtD
Sitaxentan—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000164	0.00149	CbGpPWpGaD
Sitaxentan—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000164	0.000574	CcSEcCtD
Sitaxentan—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000163	0.000573	CcSEcCtD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000163	0.00149	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000162	0.00148	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000161	0.000563	CcSEcCtD
Sitaxentan—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00016	0.00056	CcSEcCtD
Sitaxentan—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00016	0.00056	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.00016	0.00146	CbGpPWpGaD
Sitaxentan—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000157	0.000551	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000157	0.000551	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000157	0.00143	CbGpPWpGaD
Sitaxentan—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000157	0.000549	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000155	0.00142	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000155	0.000543	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000153	0.0014	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000153	0.00139	CbGpPWpGaD
Sitaxentan—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000152	0.000534	CcSEcCtD
Sitaxentan—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000152	0.000534	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	0.000152	0.00139	CbGpPWpGaD
Sitaxentan—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000151	0.000529	CcSEcCtD
Sitaxentan—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000149	0.000523	CcSEcCtD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000148	0.00135	CbGpPWpGaD
Sitaxentan—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000147	0.000516	CcSEcCtD
Sitaxentan—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000147	0.000516	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000145	0.00132	CbGpPWpGaD
Sitaxentan—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000144	0.000506	CcSEcCtD
Sitaxentan—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000144	0.000504	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000144	0.00131	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000143	0.00131	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	0.000142	0.00129	CbGpPWpGaD
Sitaxentan—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000142	0.000496	CcSEcCtD
Sitaxentan—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000142	0.000496	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000142	0.00129	CbGpPWpGaD
Sitaxentan—Rash—Formoterol—chronic obstructive pulmonary disease	0.00014	0.000492	CcSEcCtD
Sitaxentan—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00014	0.000492	CcSEcCtD
Sitaxentan—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00014	0.000492	CcSEcCtD
Sitaxentan—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00014	0.000492	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.00014	0.00128	CbGpPWpGaD
Sitaxentan—Headache—Formoterol—chronic obstructive pulmonary disease	0.00014	0.000489	CcSEcCtD
Sitaxentan—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00014	0.000489	CcSEcCtD
Sitaxentan—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000139	0.000489	CcSEcCtD
Sitaxentan—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000139	0.000488	CcSEcCtD
Sitaxentan—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000139	0.000487	CcSEcCtD
Sitaxentan—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000139	0.000486	CcSEcCtD
Sitaxentan—Rash—Montelukast—chronic obstructive pulmonary disease	0.000138	0.000482	CcSEcCtD
Sitaxentan—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000137	0.000482	CcSEcCtD
Sitaxentan—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000137	0.000481	CcSEcCtD
Sitaxentan—Headache—Montelukast—chronic obstructive pulmonary disease	0.000137	0.000479	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000136	0.00124	CbGpPWpGaD
Sitaxentan—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000475	CcSEcCtD
Sitaxentan—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000472	CcSEcCtD
Sitaxentan—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000134	0.000469	CcSEcCtD
Sitaxentan—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000133	0.000467	CcSEcCtD
Sitaxentan—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000133	0.000466	CcSEcCtD
Sitaxentan—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000133	0.000465	CcSEcCtD
Sitaxentan—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000132	0.000464	CcSEcCtD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000132	0.00121	CbGpPWpGaD
Sitaxentan—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000132	0.000464	CcSEcCtD
Sitaxentan—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000132	0.000464	CcSEcCtD
Sitaxentan—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000132	0.000462	CcSEcCtD
Sitaxentan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000131	0.00119	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000131	0.00119	CbGpPWpGaD
Sitaxentan—Nausea—Montelukast—chronic obstructive pulmonary disease	0.00013	0.000454	CcSEcCtD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000129	0.00117	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000128	0.00117	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000127	0.00116	CbGpPWpGaD
Sitaxentan—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000126	0.00044	CcSEcCtD
Sitaxentan—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000125	0.000438	CcSEcCtD
Sitaxentan—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000124	0.000436	CcSEcCtD
Sitaxentan—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000124	0.000435	CcSEcCtD
Sitaxentan—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000433	CcSEcCtD
Sitaxentan—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000121	0.000423	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000119	0.00109	CbGpPWpGaD
Sitaxentan—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000118	0.000413	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000117	0.00107	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000116	0.00106	CbGpPWpGaD
Sitaxentan—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000115	0.000404	CcSEcCtD
Sitaxentan—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000115	0.000401	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000114	0.00104	CbGpPWpGaD
Sitaxentan—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000112	0.000392	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000112	0.00102	CbGpPWpGaD
Sitaxentan—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000391	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.00011	0.00101	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000109	0.000999	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000109	0.000998	CbGpPWpGaD
Sitaxentan—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000109	0.000382	CcSEcCtD
Sitaxentan—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000382	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	0.000109	0.000994	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000109	0.000994	CbGpPWpGaD
Sitaxentan—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000379	CcSEcCtD
Sitaxentan—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000377	CcSEcCtD
Sitaxentan—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000107	0.00098	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000107	0.00098	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000104	0.000948	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000104	0.000948	CbGpPWpGaD
Sitaxentan—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.000362	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000101	0.000919	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.0001	0.000913	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.0001	0.000913	CbGpPWpGaD
Sitaxentan—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	9.97e-05	0.000349	CcSEcCtD
Sitaxentan—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	9.94e-05	0.000348	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	9.93e-05	0.000906	CbGpPWpGaD
Sitaxentan—Anaemia—Prednisone—chronic obstructive pulmonary disease	9.93e-05	0.000348	CcSEcCtD
Sitaxentan—Agitation—Prednisone—chronic obstructive pulmonary disease	9.87e-05	0.000346	CcSEcCtD
Sitaxentan—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	9.87e-05	0.0009	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	9.79e-05	0.000893	CbGpPWpGaD
Sitaxentan—Malaise—Prednisone—chronic obstructive pulmonary disease	9.69e-05	0.00034	CcSEcCtD
Sitaxentan—Vertigo—Prednisone—chronic obstructive pulmonary disease	9.65e-05	0.000338	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	9.59e-05	0.000875	CbGpPWpGaD
Sitaxentan—Urticaria—Prednisolone—chronic obstructive pulmonary disease	9.58e-05	0.000336	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	9.49e-05	0.000866	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	9.45e-05	0.000862	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	9.36e-05	0.000854	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	9.34e-05	0.000852	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	9.13e-05	0.000832	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	9.09e-05	0.000829	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	9.08e-05	0.000318	CcSEcCtD
Sitaxentan—Discomfort—Prednisone—chronic obstructive pulmonary disease	9.03e-05	0.000317	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	9e-05	0.000821	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	8.89e-05	0.000312	CcSEcCtD
Sitaxentan—Oedema—Prednisone—chronic obstructive pulmonary disease	8.77e-05	0.000307	CcSEcCtD
Sitaxentan—Infection—Prednisone—chronic obstructive pulmonary disease	8.71e-05	0.000305	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	8.65e-05	0.000789	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	8.64e-05	0.000788	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	8.6e-05	0.000301	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	8.57e-05	0.000782	CbGpPWpGaD
Sitaxentan—Tachycardia—Prednisone—chronic obstructive pulmonary disease	8.56e-05	0.0003	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	8.53e-05	0.000778	CbGpPWpGaD
Sitaxentan—Skin disorder—Prednisone—chronic obstructive pulmonary disease	8.51e-05	0.000298	CcSEcCtD
Sitaxentan—Anorexia—Prednisone—chronic obstructive pulmonary disease	8.36e-05	0.000293	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	8e-05	0.00073	CbGpPWpGaD
Sitaxentan—Dizziness—Prednisolone—chronic obstructive pulmonary disease	7.98e-05	0.00028	CcSEcCtD
Sitaxentan—Insomnia—Prednisone—chronic obstructive pulmonary disease	7.93e-05	0.000278	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	7.85e-05	0.000716	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	7.84e-05	0.000716	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.79e-05	0.000711	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	7.74e-05	0.000706	CbGpPWpGaD
Sitaxentan—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	7.72e-05	0.00027	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	7.63e-05	0.000696	CbGpPWpGaD
Sitaxentan—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	7.62e-05	0.000267	CcSEcCtD
Sitaxentan—Rash—Prednisolone—chronic obstructive pulmonary disease	7.61e-05	0.000267	CcSEcCtD
Sitaxentan—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	7.6e-05	0.000266	CcSEcCtD
Sitaxentan—Fatigue—Prednisone—chronic obstructive pulmonary disease	7.56e-05	0.000265	CcSEcCtD
Sitaxentan—Headache—Prednisolone—chronic obstructive pulmonary disease	7.56e-05	0.000265	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.5e-05	0.000684	CbGpPWpGaD
Sitaxentan—Constipation—Prednisone—chronic obstructive pulmonary disease	7.5e-05	0.000263	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—KL—chronic obstructive pulmonary disease	7.44e-05	0.000679	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	7.22e-05	0.000253	CcSEcCtD
Sitaxentan—Nausea—Prednisolone—chronic obstructive pulmonary disease	7.17e-05	0.000251	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.97e-05	0.000636	CbGpPWpGaD
Sitaxentan—Urticaria—Prednisone—chronic obstructive pulmonary disease	6.96e-05	0.000244	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	6.96e-05	0.000635	CbGpPWpGaD
Sitaxentan—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	6.93e-05	0.000243	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	6.87e-05	0.000626	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	6.55e-05	0.000597	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	6.46e-05	0.000589	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	6.46e-05	0.000226	CcSEcCtD
Sitaxentan—Asthenia—Prednisone—chronic obstructive pulmonary disease	6.29e-05	0.00022	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	6.18e-05	0.000564	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.14e-05	0.00056	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	6.02e-05	0.000549	CbGpPWpGaD
Sitaxentan—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	6e-05	0.00021	CcSEcCtD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.94e-05	0.000541	CbGpPWpGaD
Sitaxentan—Dizziness—Prednisone—chronic obstructive pulmonary disease	5.8e-05	0.000203	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.73e-05	0.000523	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.71e-05	0.00052	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	5.63e-05	0.000513	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	5.61e-05	0.000512	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	5.58e-05	0.000509	CbGpPWpGaD
Sitaxentan—Vomiting—Prednisone—chronic obstructive pulmonary disease	5.57e-05	0.000195	CcSEcCtD
Sitaxentan—Rash—Prednisone—chronic obstructive pulmonary disease	5.53e-05	0.000194	CcSEcCtD
Sitaxentan—Dermatitis—Prednisone—chronic obstructive pulmonary disease	5.52e-05	0.000194	CcSEcCtD
Sitaxentan—Headache—Prednisone—chronic obstructive pulmonary disease	5.49e-05	0.000193	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.47e-05	0.000499	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	5.44e-05	0.000496	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5.37e-05	0.00049	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.22e-05	0.000477	CbGpPWpGaD
Sitaxentan—Nausea—Prednisone—chronic obstructive pulmonary disease	5.21e-05	0.000183	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.06e-05	0.000461	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	5.01e-05	0.000457	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.99e-05	0.000455	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	4.96e-05	0.000453	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	4.92e-05	0.000449	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.63e-05	0.000423	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.61e-05	0.000421	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	4.59e-05	0.000419	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.57e-05	0.000417	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	4.57e-05	0.000417	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	4.48e-05	0.000409	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.41e-05	0.000402	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.19e-05	0.000382	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.17e-05	0.00038	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.1e-05	0.000374	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.92e-05	0.000357	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.76e-05	0.000343	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.74e-05	0.000341	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	3.64e-05	0.000332	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.45e-05	0.000315	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.39e-05	0.000309	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	3.32e-05	0.000303	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.32e-05	0.000303	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.15e-05	0.000288	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.04e-05	0.000277	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3e-05	0.000274	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	2.96e-05	0.00027	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.84e-05	0.000259	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.75e-05	0.000251	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.69e-05	0.000246	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.69e-05	0.000245	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	2.66e-05	0.000242	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.6e-05	0.000237	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.48e-05	0.000226	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.47e-05	0.000226	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.45e-05	0.000224	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.42e-05	0.000221	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	2.42e-05	0.000221	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	2.42e-05	0.000221	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.26e-05	0.000206	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.23e-05	0.000204	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	2.21e-05	0.000202	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.04e-05	0.000186	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.04e-05	0.000186	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.86e-05	0.00017	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.86e-05	0.00017	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.84e-05	0.000168	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.71e-05	0.000156	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.7e-05	0.000155	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.67e-05	0.000153	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.62e-05	0.000148	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.62e-05	0.000147	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	1.6e-05	0.000146	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.56e-05	0.000142	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.48e-05	0.000135	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	1.46e-05	0.000133	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.34e-05	0.000123	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.12e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.1e-05	0.000101	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	1.1e-05	0.000101	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	1.05e-05	9.62e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.03e-05	9.39e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	1.01e-05	9.17e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.76e-06	8.9e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	9.62e-06	8.78e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	6.63e-06	6.05e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	6.34e-06	5.79e-05	CbGpPWpGaD
